Abstract:Background The interplay between the gut microbiome and immune responses in cancer remains poorly understood. We showed that gut microbiome changes are closely associated with development of lung adenocarcinoma (LUAD) in a human-relevant, tobacco-associated mouse model (Gprc5a-/-; G).1 Knockout of the antimicrobial protein Lcn2 (Gprc5a-/-/Lcn2-/-; GL) further reduced microbial diversity while enhancing inflammation and tumor development.1 We thus hypothesized that microbial dysbiosis in the gut, such as that incurred by loss of Lcn2, may exacerbate LUAD development and influence response to immune checkpoint blockade (ICB). Methods We used fecal microbiota transfer (FMT) in syngeneic and tobacco carcinogenesis models. Gut microbiome composition was assessed using 16S rDNA-Seq analysis, chemokines were quantified in murine sera, and the tumor immune microenvironment (TIME) and gut immune milieu were comprehensively studied using single-cell RNA-sequencing and flow cytometry. Results Syngeneic G mice receiving FMT from GL donors (G < GL) exhibited significantly increased tumor growth compared to G < G mice. This effect was recapitulated in an independent syngeneic model (KrasG12D LKR13 cells in wild-type mice) and tobacco carcinogen-exposed G < GL mice. Analysis of fecal pellets using 16S rDNA-Seq revealed significant differences in gut beta diversity between G < G and G < GL mice, with elevated abundance of tumor-promoting Alistipes2 and reduced levels of immunotherapy-favorable taxa Ruminoccocus and Akkermansia.3 Flow cytometry analysis of the colonic lamina propria demonstrated an inflamed environment in G < GL mice with increased inflammatory immune cell frequency. This local gut inflammation was accompanied by a systemic inflammatory response, as indicated by elevated inflammatory chemokines in the sera. Single-cell RNA-sequencing and flow cytometry analysis of tumors revealed an enhanced immunosuppressive phenotype in the TIME of G < GL mice, including increased fractions of T regulatory and exhausted T cells, along with reduced levels of activated T cells. Flow cytometry confirmed enhanced immunosuppression in G < GL mice, including increased fractions of myeloid-derived suppressor cells in the TIME. The dysbiotic gut, with its associated systemic inflammation and immunosuppression of the TIME, significantly impacted the response to ICB, with G < GL mice demonstrating reduced response and sensitivity to anti-PD1 treatment compared to G < G mice. Conclusions Our findings show that gut microbiome dysbiosis fosters lung cancer development by promoting immunosuppression, perhaps via a local and systemic gut microbiota-immune system crosstalk (figure 1). Modulating the gut microbiome may offer promising strategy for interception or early treatment of lung cancer. Acknowledgements Supported in part by National Cancer Institute (NCI) grants R01CA205608 and R01CA248731 (to H. Kadara). References Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, et al. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci. 2022;23(18):10930. Available online: https://doi.org/10.3390/ijms231810930 Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, Hackl H, Pfister A, Schilling J, Moser PL, Kempster SL, Swidsinski A, Orth Höller D, Weiss G, Baines JF, Kaser A, Tilg H. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe. 2016;19(4):455–469. doi: 10.1016/j.chom.2016.03.007 Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi: 10.1038/s41591–020-01224–2

Dysregulation of NK and CD8+T Cells by the Microbiota Promotes the Progression of Lung Cancer

Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer

Role of Respiratory System Microbiota in Development of Lung Cancer and Clinical Application

Microbiota Modulate Tumoral Immune Surveillance in Lung Through a Γδt17 Immune Cell-Dependent Mechanism.

Abstract C021: Tumor-associated microbiota suppresses anti-tumor immunity by driving cDC1 dysfunction in lung cancer

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

Abstract 2883: Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

Human Microbiota: a Crucial Gatekeeper in Lung Cancer Initiation, Progression, and Treatment

Dysbiosis of lower respiratory tract microbiome are associated with proinflammatory states in non‐small cell lung cancer patients

Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected

Host-Microbiome Interaction in Lung Cancer

Special tissue microbiota such as Cyanobacteria are associated with the immune microenvironment of lung adenocarcinoma

Microbiome Dysbiosis in Lung Cancer: from Composition to Therapy

1330 Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

The Role of Respiratory Microbiota in Lung Cancer.

The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

P1.01-44 the Role of Microbiota on the Development of Non-Small-Cell Lung Cancer

Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer

Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study